Takeda's Maribavir US Application For Post-Transplant CMV Infection Under Review

by Vandana Singh, Benzinga Editor

May 21, 2021 8:16 AM | 1 min read |

The FDA has accepted for review Takeda Pharmaceutical Co Ltd's (NYSE TAK) marketing application for maribavir for cytomegalovirus (CMV) Infection.
The application under priority review is seeking maribavir approval CMV infection in those that are refractory with or without resistance (R/R), in solid organ transplant (SOT), or hematopoietic cell transplant (HCT) recipients.
It is an inflection year for Takeda's pipeline, with up to six regulatory submissions and four potential approvals anticipated by the end of the fiscal year 2021.
Maribavir is Takeda's fourth new molecular entity accepted for regulatory review in six months.
Price Action: TAK shares are up 0.98% at $17.49 in the premarket session on the last check Friday.
Related content: Benzinga's Full FDA Calendar

Posted In:

Biotech News Health Care FDA General Briefs cytomegalovirus

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.